Close

JPMorgan Starts Prime Medicine (PRME) at Overweight

November 14, 2022 3:26 AM EST Send to a Friend
JPMorgan analyst Eric Joseph initiates coverage on Prime Medicine (NASDAQ: PRME) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login